Literature DB >> 19230156

Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses.

Colin A Russell1, Terry C Jones, Ian G Barr, Nancy J Cox, Rebecca J Garten, Vicky Gregory, Ian D Gust, Alan W Hampson, Alan J Hay, Aeron C Hurt, Jan C de Jong, Anne Kelso, Alexander I Klimov, Tsutomu Kageyama, Naomi Komadina, Alan S Lapedes, Yi P Lin, Ana Mosterin, Masatsugu Obuchi, Takato Odagiri, Albert D M E Osterhaus, Guus F Rimmelzwaan, Michael W Shaw, Eugene Skepner, Klaus Stohr, Masato Tashiro, Ron A M Fouchier, Derek J Smith.   

Abstract

Annual influenza epidemics in humans affect 5-15% of the population, causing an estimated half million deaths worldwide per year [Stohr K. Influenza-WHO cares. Lancet Infectious Diseases 2002;2(9):517]. The virus can infect this proportion of people year after year because the virus has an extensive capacity to evolve and thus evade the immune response. For example, since the influenza A(H3N2) subtype entered the human population in 1968 the A(H3N2) component of the influenza vaccine has had to be updated almost 30 times to track the evolution of the viruses and remain effective. The World Health Organization Global Influenza Surveillance Network (WHO GISN) tracks and analyzes the evolution and epidemiology of influenza viruses for the primary purpose of vaccine strain selection and to improve the strain selection process through studies aimed at better understanding virus evolution and epidemiology. Here we give an overview of the strain selection process and outline recent investigations into the global migration of seasonal influenza viruses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19230156     DOI: 10.1016/j.vaccine.2008.07.078

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  117 in total

1.  Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses.

Authors:  Matthew R Sandbulte; Kim B Westgeest; Jin Gao; Xiyan Xu; Alexander I Klimov; Colin A Russell; David F Burke; Derek J Smith; Ron A M Fouchier; Maryna C Eichelberger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Identification of a small-molecule entry inhibitor for filoviruses.

Authors:  Arnab Basu; Bing Li; Debra M Mills; Rekha G Panchal; Steven C Cardinale; Michelle M Butler; Norton P Peet; Helena Majgier-Baranowska; John D Williams; Ishan Patel; Donald T Moir; Sina Bavari; Ranjit Ray; Michael R Farzan; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 3.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

Review 4.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

5.  Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus.

Authors:  Jason R Wilson; Zhu Guo; Wen-Pin Tzeng; Rebecca J Garten; Xu Xiyan; Elisabeth G Blanchard; Kristy Blanchfield; James Stevens; Jacqueline M Katz; Ian A York
Journal:  Virology       Date:  2015-08-27       Impact factor: 3.616

6.  Antigenic distance measurements for seasonal influenza vaccine selection.

Authors:  Zhipeng Cai; Tong Zhang; Xiu-Feng Wan
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

7.  Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates.

Authors:  Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto
Journal:  Clin Infect Dis       Date:  2013-11-13       Impact factor: 9.079

8.  The regulatory T cells in anti-influenza antibody response post influenza vaccination.

Authors:  Shih-Min Wang; Ming-Hsun Tsai; Huan-Yao Lei; Jen-Ren Wang; Ching-Chuan Liu
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

9.  Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.

Authors:  Carolien E van de Sandt; YingYing Dou; Stella E Vogelzang-van Trierum; Kim B Westgeest; Mark R Pronk; Albert D M E Osterhaus; Ron A M Fouchier; Guus F Rimmelzwaan; Marine L B Hillaire
Journal:  J Gen Virol       Date:  2015-04-21       Impact factor: 3.891

10.  Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.

Authors:  Peter H Goff; Tomoko Hayashi; Wenqian He; Shiyin Yao; Howard B Cottam; Gene S Tan; Brian Crain; Florian Krammer; Karen Messer; Minya Pu; Dennis A Carson; Peter Palese; Maripat Corr
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.